Business Wire

CA-ALORICA

4.3.2024 10:01:32 CET | Business Wire | Press release

Share
Alorica Introduces ReVoLT – Breakthrough Technology Enabling Real-Time Voice Translation for 75 Languages and 200 Dialects, a Game Changer in Multilingual CX Delivery

Alorica Inc., a global customer experience (CX) leader, announced today the launch of its Real-time Voice Language Translation (ReVoLT), effectively eliminating language barriers during live customer interactions. This offering is the centrepiece of Alorica Clear, an AI-powered solution suite that revolutionises how businesses communicate with their global customer base through seamless voice language translation, accent localisation and background noise cancellation. The services are enabled by an exclusive linguistic processing platform that applies AI to offer translation capabilities designed for multilingual CX across digital and voice channels.

As companies personalise and localise their customer experiences, they face language barriers and cultural nuances that complicate operations and challenge ROI. ReVoLT removes these pain points by providing real-time, bi-directional voice translation in 75 languages. By integrating this technology, organisations can set up their service operations anywhere and support customers across the globe in their native language, improving service and reducing costs by up to 50%.

“The demand for multilingual service is exploding due to an increasingly interconnected world where brands engage consumers through personalised experiences,” stated Mike Clifton, Alorica’s Chief Growth & Transformation Officer. “Customers place high value on localisation, but CX leaders are struggling to efficiently scale their contact centres across multiple geographies. Multilingual support has historically required fragmented queues or locations, which adds complexity and cost while reducing quality. ReVoLT is our strategic response to this growing need, empowering our clients to deliver centralised, effective, and culturally sensitive customer support while achieving significant savings and improved service.”

According to industry data, 29% of businesses cite losing customers because they did not offer multilingual support, and 70% of end users say they feel more loyal to companies that provide services in their native language. Alorica Clear enriches customer interactions and enhances business outcomes through the transformative power of AI, machine translation and large language models.

The Alorica Clear solution suite eliminates friction in global CX delivery through:

  • Real-Time Voice Translation – ReVoLT provides bi-directional voice translation, grammar correction and transcription for 75 languages and 200 dialects with high scalability and security.
  • Digital Translation – Supporting over 100 languages and dialects, agents can seamlessly deliver multilingual digital transactions via chat, email, and documents.
  • Multilingual Cognitive Assistant – Interprets and resolves inquiries digitally in over 100 languages and is uniquely trained to brand voice and objectives.
  • Accent Localisation – Mitigates agents' accents during live interactions, adapting to the natural language of the customer to ensure comprehension.
  • Noise Cancellation – Eliminates background noise and distractions, tailored to Alorica Anywhere, the company’s work-at-home solution.

“We believe language personalisation is one of the most compelling applications of this exclusive technology, removing longstanding barriers to providing localised service with high quality and efficiency. Real-time voice language translation embodies our commitment to seamless and effective customer experiences, regardless of language differences,” shared Clifton.

Alorica Clear joins the portfolio of technology-infused offerings by Alorica IQ – the company’s digital and innovation practice focused on user experience design, technology solutions and analytics. Experience Alorica Clear’s exclusive Real-Time Voice Language Translation capabilities here.

About Alorica

Alorica creates insanely great digital customer experiences at scale. Our team of 100,000 solutionists, technologists and operators partner with global brands and disruptive innovators to deliver digitally charged, tailored interactions customers crave. With a track record of creating long-term loyalty, Alorica brings actionable insights, proven processes and CX leadership that deliver outcomes critical to clients’ objectives, whether they’re focused on digital optimisation, customer engagement or market expansion. Our digital practice— Alorica IQ—designs, integrates and optimises best-of-breed technology solutions across the customer experience to improve service and increase operational efficiency. Alorica drives CX innovation for the best clients around the globe from its award-winning operations in 19 countries worldwide. To learn more, visit www.alorica.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240304683403/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye